

Combination Activity of Standard Antituberculosis Drugs and Extracts of Medicinal Plants Commonly Used in Traditional Treatment of Tuberculosis in Uganda

Moses Mpeirwe (✉ mmpeirwe@must.ac.ug)

Mbarara University of Science and Technology

Kevin Komakech

Makerere University

Duncan Ssesazi

Mbarara University of Science and Technology

Patrick Engeu Ogwang

Mbarara University of Science and Technology

Joel Bazira

Mbarara University of Science and Technology

Research Article

Keywords: Combination activity, medicinal plants, *Zanthoxylum leprieurii*, *Rubia cordifolia*, antituberculosis drugs

Posted Date: October 5th, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-3338947/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Additional Declarations: No competing interests reported.

Abstract

Background

Despite the increasing acceptance of medicinal plant use in combination with conventional antituberculosis drugs in treatment of tuberculosis (TB) in Uganda, there is paucity of knowledge on their combination effect. This research aimed to find combination activity of standard antituberculosis drugs with extracts of *Zanthoxylum leprieurii* and *Rubia cordifolia*, the two common antituberculosis medicinal plants, against pansensitive (H37Rv) and multi-drug resistant (MDR) *Mycobacterium tuberculosis*.

Methods

Two reference MTB strains (H37Rv and MDR strain) were inoculated on Middlebrook 7H11 medium containing a combination of standard anti-TB drugs and methanol extracts of *Z. leprieurii* and *R. cordifolia* at varying concentrations. The number of colonies on the plates were observed and counted weekly for up to 8 weeks. *In vitro* combination activity was determined using proportion method. Mean percentage inhibition was calculated for the reduction of number of colonies on drug-extract combination medium in relation to drug-extract-free control medium.

Results

Drug-extract combinations showed good combination effect against *Mycobacterium tuberculosis* strains when compared with individual standard anti-TB drugs. This was more evident with MDR strain. There was however a reduction in percentage inhibition when extracts were combined with ethambutol and streptomycin against H37Rv strain.

Conclusions

Therefore, use of medicinal plants in combination with conventional antituberculosis drugs in TB treatment should be done with caution especially with susceptible cases.

1. Introduction

Tuberculosis (TB) is a communicable disease that has caused ill health to humanity for many years. TB was the leading cause of death worldwide from a single infectious agent until 2020, when the coronavirus (COVID-19) pandemic emerged. According to the World Health Organization (WHO), approximately 10.6 million people fell ill of TB in 2021, which represents a 4.5% increase from 10.1 million in 2020. The disease also claimed 1.6 million lives globally, with the burden mainly confined within 30 countries, which account for over 86% of all cases [1].

Although TB treatment is effective, its duration is long, and anti-TB drugs can cause serious side effects. These factors, among others, confer poor adherence of patients to chemotherapy, and patients frequently abandon

treatment. This, consequently, may result in secondary resistance to anti-TB drugs and eventual spread of drug-resistant bacilli. Ultimately, this leads to primary resistance (presence of resistant *Mycobacterium tuberculosis* in patients with no prior history of treatment)[2].

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB continues to be a public health threat. In 2021, the World Health Organization estimated that the proportion of people with MDR-TB to be 3.6% and 18% among new and previously treated cases respectively. In the same year, 25,038 new cases of XDR were detected globally[1]. The standard short-course treatment of TB requires a combination of anti-TB drugs with a duration of six months. This regimen has been found to give an 85–90% success rate in 100% complaint TB patients. Patients with MDR-TB are treated with a regimen of four to five anti-TB drugs for a period of greater than 15 months after a negative culture is obtained[3]. This long duration, accompanied by frequent serious adverse effects, leads to poor compliance and cessation of treatment[4, 5].

More innovative inventions and developments are needed to accelerate the eradication of tuberculosis globally. Medicinal plants offer great hope to meet the pressing need for new antituberculosis regimens. Many plant species have extensively been studied for their activity against *Mycobacterium tuberculosis*. Recently, a number of studies have reported that native Ugandan plants used traditionally for respiratory diseases and other ailments have antimycobacterial activity [6–10].

It is also not uncommon for patients on conventional antituberculosis treatment to combine it with traditional herbal medicines. In Uganda, it has been reported that traditional medicine use is between 60–80%[11, 12]. However, the combination activity of medicinal plants commonly used by traditional medicine practitioners (TMPs) in Uganda[6] and standard antituberculosis drugs has rarely been determined. This study therefore aimed to evaluate the *in vitro* combination activity of standard anti-TB drugs and extracts of *Zanthoxylum leprieurii* and *Rubia cordifolia* against pansensitive H37Rv and MDR-TB strains.

2. Materials and Methods

2.1 Plant collection

Zanthoxylum leprieurii stem bark of a mature plant was collected from Mabira forest in Buikwe district, Central Uganda. *Rubia cordifolia* was picked from Kagamba village in Ntungamo District, southwestern Uganda. Both plants were collected with the help of a botanist. A voucher specimen for *Z. leprieurii* was deposited in the herbarium of Makerere University, Kampala, Uganda with accession number 50,925. Permission to collect plant parts from Mabira forest was obtained from National Forest Authority (NFA), Kampala, Uganda. Collected plant parts were air dried under the shed for approximately 2 weeks and powdered separately using a blender into fine powder. They were stored in dark containers and wrapped in black polythene bags until required for extraction.

2.2 Extraction

The powdered plant materials were extracted using 80% methanol[13, 14]. The powdered plant parts, each weighing 200 g, were extracted with 1000 mL of the extraction solvent by cold maceration at room temperature (24°C) for 72 h with frequent agitation[15]. The filtrate was concentrated using a rotary vacuum evaporator including a water bath set at a temperature of 45°C. The concentrate was frozen at -80°C and then lyophilized

using a freeze dryer. The lyophilized material was then air-dried, measured and packed in glass amber bottles. They were labeled and stored at 4°C for future use.

2.3 Mycobacterium strains

Two strains were used: the reference drug-susceptible strain *Mycobacterium tuberculosis*, H37Rv, and MDR-TB. *Mycobacterium tuberculosis* strains were provided by the Mycobacteriology BSL-3 Laboratory, Department of Microbiology, College of Health Sciences, Makerere University, Uganda. They were subcultured on Middlebrook 7H11 agar for 2 weeks. Freshly growing colonies were carefully scraped from the surfaces of the media. The colonies were suspended in 10 mL of normal saline. The turbidity of the suspension was adjusted to that of a McFarland standard number 1 by either adding more cells to the suspension or diluting with normal saline.

2.4 Reagents and antibiotics

Rifampicin (RMP), Isoniazid (INH), Ethambutol (EMB) and Streptomycin (STR) were used as standard antibiotics. A stock concentration of 100 µg/ml of each drug was prepared using sterile distilled water except for rifampicin. In addition, Dimethyl sulfoxide (DMSO) was used as a solvent to prepare both rifampicin and 10,000 µg/ml stock concentration of test plant extracts.

2.5 Preliminary study

The stock methanol extracts were diluted using DMSO and incorporated into Middlebrook 7H11 medium (Difco Laboratories, Detroit, MI, USA) supplemented with 10% oleic acid, albumin, dextrose and catalase (OADC) (Becton Dickinson) to attain concentrations of 50, 100, 500 and 1000 µg/mL. The results from this preliminary study were used to establish the extract concentrations to be combined with standard antituberculosis drugs. Extract-free medium with MTB was used as a positive control, and extract-free medium without MTB was used as a negative control for the assay. The previously prepared *Mycobacterium tuberculosis* strains (1 MacFarland standard) were inoculated onto each plate except the negative control. All plates were incubated at 37°C for 8 weeks. The number of colonies was enumerated weekly.

2.6 Drug-Extract Combination Assay

The effects of the combination of *Zanthoxylum leprieurii* and *Rubia cordifolia* methanol extracts with RMP, INH, EMB and STR were determined in 7H11 agar as described by Prabasiwi Nur Fauziyah, 2017[16]. The standard extract concentrations used in this assay were 500, 100 and 50 µg/mL for both plant extracts. The standard antituberculosis drug concentrations used in combinations were 1 µg/mL, 0.2 µg/mL, 7.5 µg/mL and 2 µg/mL for rifampicin, isoniazid, ethambutol and streptomycin, respectively[17]. Two series of stock solutions were prepared by diluting each extract and standard drug in DMSO and sterile water, respectively, except for the *Z. leprieurii* extract, which was diluted in DMSO. The concentrations of the stock solutions used were 10,000 µg/mL for extracts and 100 µg/mL for standard drugs. To make a 1:500 combination of rifampicin and the extracts, 1.25 mL of 10,000 µg/mL extract stock solution and 0.25 mL of 100 µg/mL rifampicin stock solution were added to 23.5 mL of sterile Middlebrook 7H11 medium and shaken gently until mixed homogeneously. The same procedure was repeated for the rest of the combinations as summarized in Table 1 below. The entire 25 mL of the extract-drug-medium solution was poured onto a 90 mm petri dish and allowed to cool at room temperature.

A total of 100 µL of MTB strains (1 McFarland standard) was inoculated onto each of the petri dishes containing extract-drug-medium at varying concentrations, except for the negative controls (medium with no extract and no drug). This activity assay was done in duplicate. After inoculation, the petri dishes were sealed using parafilm and incubated at 37°C. The number of colonies was observed and counted weekly for up to 8 weeks.

Table 1
Summary of the preparation of the combination of *Zanthoxylum leprieurii* and *Rubia cordifolia* extracts with standard antituberculosis drugs.

Standard Drug	Standard drug stock concentration (µg/mL)	Drug stock volume (mL)	Extract stock concentration (µg/mL)	Extract stock volume (mL)	Media volume (mL)	Total volume (mL)	Final drug-Extract concentration
Rifampicin	100	0.25	10,000	1.25	23.5	25	1:500
Rifampicin	100	0.25	10,000	0.25	24.5	25	1:100
Rifampicin	100	0.25	10,000	0.125	24.625	25	1:50
Isoniazid	100	0.05	10,000	1.25	23.7	25	0.2:500
Isoniazid	100	0.05	10,000	0.25	24.7	25	0.2:100
Isoniazid	100	0.05	10,000	0.125	24.825	25	0.2:50
Ethambutol	100	1.875	10,000	1.25	21.875	25	7.5:500
Ethambutol	100	1.875	10,000	0.25	22.875	25	7.5:100
Ethambutol	100	1.875	10,000	0.125	23.0	25	7.5:50
Streptomycin	100	0.5	10,000	1.25	23.25	25	2:500
Streptomycin	100	0.5	10,000	0.25	24.25	25	2:100
Streptomycin	100	0.5	10,000	0.125	24.375	25	2:50

3. Results

The study was performed as an antimycobacterial assay. Data collected were MTB colony counts on 7H11 media for 8 weeks. The collected data were then processed using the proportion method, which resulted in a percentage inhibition as shown in Table 2 for the preliminary study and Table 3 for the extract-drug combination assay.

Starting with the preliminary study (individual extract antimycobacterial activity), the methanol extract of *Zanthoxylum leprieurii* exhibited 100% growth inhibition against both H37Rv and MDR *Mycobacterium tuberculosis* strains at concentration of 100 µg/mL. Both extracts showed preferentially high inhibition rates against MDR strain. A concentration of 500 µg/mL was used as the highest concentration for both *Z. leprieurii* and *R. cordifolia* extracts for the combination study because it gave 100% growth inhibition for both MTB strains. The results indicated a dose–response relationship, thus justifying the lowering of extract concentrations to 50 µg/mL in the combination assay.

Table 2

Percentage inhibition of different plant extract concentrations against pansensitive MTB (H37Rv) and multidrug-resistant (MDR) *Mycobacterium tuberculosis*

<i>Mycobacterium tuberculosis</i> strains					
Botanical Name	Concentration (µg/mL)	H37Rv		MDR	
		Mean CFU*	Mean % Inhibition	Mean CFU*	Mean % Inhibition
Control (-)	-	0		0	
Control (+)	-	480	-	17	-
<i>Zanthoxylum leprieurii</i>	50	91	81	02	88
	100	0	100	0	100
	500	0	100	0	100
	1000	0	100	0	100
<i>Rubia cordifolia</i>	50	45	91	6	65
	100	105	78	0	100
	500	0	100	0	100
	1000	0	100	0	100

* Colony Forming Unit.

The results indicated an additive effect when rifampicin was combined with both plant extracts against the H37Rv strain. Specifically, both plant extracts exhibited complete (100%) inhibition at a lower concentration of 50 µg/mL against the pansensitive MTB strain when combined with rifampicin. An increased potency for the combination of ethambutol with the extracts against the MDR-TB strain was observed. In contrast, the results indicated a decrease in potency for the combination of rifampicin and isoniazid against MDR-TB isolates. Noticeably, *Z. leprieurii* extract alone exhibited 100% growth inhibition at 50 µg/mL, while its combination with isoniazid at a concentration of 100 µg/mL yielded 94% and 95% inhibition against H37Rv and MDR-TB, respectively. There was a remarkable increase in the percentage inhibition of extract-drug combinations against MDR-TB compared to individual single standard anti-tuberculosis drugs. Individual standard anti-TB drugs showed a growth inhibition ranging from as low as 5–52% against MDR-MTB strain, whereas on combination with both extracts, ethambutol and streptomycin exhibited complete inhibition (100%) against the same strain.

Table 3

Percentage inhibition for different combinations of standard antituberculosis drugs and extracts against H37Rv and MDR-TB strains.

Standard Drugs	Methanol Extract	concentration in combination (µg/mL)	H37Rv		MDR	
			Mean CFU	Mean % Inhibition	Mean CFU	Mean % Inhibition
Control (+)	-	-	282	-	152	-
Rifampicin	-	-	0	100	107	29
	<i>Z.leprieurii</i>	1:500	0	100	0	100
	<i>R.cordifolia</i>	1:500	0	100	0	100
	<i>Z.leprieurii</i>	1:100	0	100	0	100
	<i>R.cordifolia</i>	1:100	0	100	17	89
	<i>Z.leprieurii</i>	1:50	0	100	22	86
	<i>R.cordifolia</i>	1:50	0	100	57	63
Control (+)	-	-	776	-	516	-
Isoniazid	-	-	118	85	491	5
	<i>Z.leprieurii</i>	0.2:500	0	100	0	100
	<i>R.cordifolia</i>	0.2:500	0	100	0	100
	<i>Z.leprieurii</i>	0.2:100	48	94	26	95
	<i>R.cordifolia</i>	0.2:100	4.5	99	40	92
	<i>Z.leprieurii</i>	0.2:50	174	76	46.5	91
	<i>R.cordifolia</i>	0.2:50	2	99	194	62
Control (+)	-	-	273	-	157	-
Ethambutol	-	-	0	100	98	38
	<i>Z.leprieurii</i>	7.5:500	0	100	0	100
	<i>R.cordifolia</i>	7.5:500	4	99	0	100
	<i>Z.leprieurii</i>	7.5:100	0	100	0	100
	<i>R.cordifolia</i>	7.5:100	20	93	0	100
	<i>Z.leprieurii</i>	7.5:50	13.5	95	0	100
	<i>R.cordifolia</i>	7.5:50	57	79	0	100

Standard Drugs	Methanol Extract	concentration in combination (µg/mL)	H37Rv		MDR	
			Mean CFU	Mean % Inhibition	Mean CFU	Mean % Inhibition
Streptomycin	-	-	0	100	76	52
	<i>Z.leprieurii</i>	2:500	0	100	0	100
	<i>R.cordifolia</i>	2:500	0	100	0	100
	<i>Z.leprieurii</i>					
	<i>R.cordifolia</i>					
	<i>Z.leprieurii</i>					
	<i>R.cordifolia</i>					
		2:100	1	99	0	100
		2:100	0	100	0	100
		2:50	10	96	3	99
		2:50	3.5	99	0	100

4. Discussion

Tuberculosis treatment is intrinsically associated with major challenges, such as complex and lengthy treatment. These have a direct impact on patient compliance and treatment outcome. Recently, there has been another concern regarding the increasing incidence of MDR and XDR tuberculosis[16]. As a result of the growing burden of drug-resistant genotypes of *Mycobacterium tuberculosis* coupled with TB-HIV coinfection, the burden of TB is now quite difficult to manage. Therefore, there is a global imperative to discover and develop new and efficacious antituberculosis agents, which should be an urgent biomedical priority[18, 19]. The plants selected in the current study are commonly used in Ugandan traditional medicine to treat tuberculosis and related ailments and have also been studied for their antimycobacterial activity against different strains of *Mycobacterium tuberculosis*[4, 10, 20]. However, little is known about the effects of combination of medicinal plants and conventional antituberculosis drugs.

This study is the first to report on the combination effect of *Zanthoxylum leprieurii* and *Rubia cordifolia* with standard antituberculosis drugs in Uganda. Previous studies have only focused on the antimycobacterial activities of these plants. It has been demonstrated that when used in combination, drugs with significantly low efficacy have therapeutic effects, even against drug-resistant strains[3]. Drug combination treatment has long been employed as a standard treatment strategy for many chronic diseases, including tuberculosis. With an objective to elucidate any potential synergistic interactions of the two commonly used medicinal plant extracts with standard first-line anti-TB drugs, we evaluated the antimycobacterial activity (percentage inhibition) of *Z. leprieurii* and *R. cordifolia* methanol extracts in combination with rifampicin, isoniazid, ethambutol and streptomycin against *M. tuberculosis* (H37Rv and MDR) strains.

Rifampicin alone exhibited 100% and 29% growth inhibition at 1 µg/mL against pansensitive H37Rv and MDR strains, respectively. On combination with *Z. leprieurii* and *R. cordifolia* extracts at a concentration of 50 µg/mL, an increase in growth inhibition was observed at 86% and 63% respectively against MDR-MTB. When each of the extracts at a concentration of 50 µg/mL was combined with isoniazid at 0.2 µg/mL, an additive effect was observed against the MDR- strain, resulting in 91% and 62% inhibition by *Z. leprieurii* and *R. cordifolia* against the MDR strain, respectively. The mechanism contributing to this synergistic effect against MDR strains is not yet known; however, there is a likelihood that since isoniazid inhibits mycolic acid synthesis, these plant extracts inhibit cell wall synthesis[3, 21].

All anti-TB drugs used in this study, rifampicin at 1 µg/mL, isoniazid at 0.2 µg/mL, ethambutol at 7.5 µg/mL and streptomycin at 2 µg/mL, exhibited a growth inhibition of not more than 52% against the MDR strain. However, a synergistic effect was observed when the standard drugs were combined with both extracts at even lower concentrations. They exhibited mycobacterial growth inhibition of between 62% and 100% against the MDR strain. This finding was consistent with other standard anti-TB drugs studied against MDR strains. This is in tandem with other previous studies that indicated that extracts of *Z. leprieurii* and *R. cordifolia* inhibited the growth of the MDR strain of *Mycobacterium tuberculosis*[4, 20, 22].

This study demonstrated that extracts of *Z. leprieurii* and *R. cordifolia* possess significant *in vitro* antimycobacterial activities against both pansensitive (H37Rv) and multidrug-resistant (MDR) MTB strains. Additionally, the extracts exhibited additive and/or synergistic interactions when combined with standard anti-tuberculosis drugs, more remarkably against MDR-MTB. This implies that pure compounds of these plants have the capability of reducing the doses and duration of treatment when combined with conventional anti-TB drugs. This may result in a multitude of advantages, ranging from preventing the emergence of resistance, increased compliancy and general reduction in global tuberculosis burden.

5. Conclusions

This study demonstrated that *Zanthoxylum leprieurii* and *Rubia cordifolia* have the potential to be developed as effective anti-TB agents used in combination with standard anti-tuberculosis drugs. Both plant extracts exhibited good combination effects with first-line anti-TB drugs, especially against the MDR strain. However, the use of these medicinal plants as traditional anti-tuberculosis remedies in combination with standard anti-TB drugs should be done cautiously, especially on individuals with susceptible tuberculosis, since not all extract-drug combinations showed good *in vitro* synergistic combination effects.

Abbreviations

MDR-TB	Multidrug-Resistant Tuberculosis
MTB	<i>Mycobacterium tuberculosis</i>
TB	Tuberculosis
TMPs	Traditional Medicine Practitioners
WHO	World Health Organization

Declarations

Ethics approval and consent to participate:

Approval was sought from Institutional Review Board of Mbarara University of Science and Technology. Permission to collect plant parts from Mabira forest was obtained from National Forest Authority (NFA), Kampala, Uganda.

Consent for publication:

Not applicable

Availability of data and materials

The data relating to this study have been included in this article and attached file.

Competing Interests:

The authors declare no conflicts of interest for this work.

Funding:

This research was funded by World Bank and Government of Uganda through PHARMBIOTRAC-African Center of Excellence (ACE II).

Authors' Contributions:

Conceptualization, MM; Data analysis and curation, MM, KK; Supervision, JB, DS, PO; writing original draft, MM; All authors reviewed the manuscript

Acknowledgments:

The authors express deepest gratitude to PHARMBIOTRAC-African Center of Excellence (ACE II) for funding this research. We are also pleased with the team from Mycobacteriology BSL-3 Laboratory, Department of Microbiology, College of Health Sciences, Makerere University for allowing this study to be carried in their facility.

References

1. WHO, G., *Global tuberculosis report 2022*. Glob Tuberc. Rep, 2022.
2. Hegeto, L.A., et al., *In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis*. Tuberculosis, 2018. **111**: p. 35-40.
3. Garg, S., et al., *Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds*. Molecules, 2022. **27**(19): p. 6714.

4. Mpeirwe, M., et al., *Anti-Mycobacterial Activity of Medicinal Plant Extracts Used in the Treatment of Tuberculosis by Traditional Medicine Practitioners in Uganda*. Pharmacology & Pharmacy, 2023. **14**(2): p. 33-42.
5. Pontali, E., M.C. Raviglione, and G.B. Migliori, *Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives*. European Respiratory Review, 2019. **28**(152).
6. Bunalema, L., et al., *Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda*. Journal of Ethnopharmacology, 2014. **151**(2): p. 999-1004.
7. Tabuti, J.R., C.B. Kukunda, and P.J. Waako, *Medicinal plants used by traditional medicine practitioners in the treatment of tuberculosis and related ailments in Uganda*. Journal of ethnopharmacology, 2010. **127**(1): p. 130-136.
8. Obakiro, S.B., et al., *Ethnobotany, ethnopharmacology, and phytochemistry of traditional medicinal plants used in the management of symptoms of tuberculosis in East Africa: a systematic review*. Tropical Medicine and Health, 2020. **48**(1): p. 1-21.
9. Oloya, B., et al., *Phytochemical screening, antimycobacterial activity and acute toxicity of crude extracts of selected medicinal plant species used locally in the treatment of tuberculosis in Uganda*. Tropical medicine and health, 2022. **50**(1): p. 1-13.
10. Tuyiringire, N., et al., *Three promising antimycobacterial medicinal plants reviewed as potential sources of drug hit candidates against multidrug-resistant tuberculosis*. Tuberculosis, 2020. **124**: p. 101987.
11. Logiel, A., et al., *Prevalence and socio-economic factors affecting the use of traditional medicine among adults of Katikale Subcounty, Moroto District, Uganda*. African Health Sciences, 2021. **21**(3): p. 1410-1417.
12. Organization, W.H., *WHO traditional medicine strategy 2002–2005*. 2002. WHO, Geneva, 2002.
13. Nguta, J.M., et al., *Antimycobacterial and cytotoxic activity of selected medicinal plant extracts*. Journal of ethnopharmacology, 2016. **182**: p. 10-15.
14. Gemechu, A., et al., *In vitro anti-mycobacterial activity of selected medicinal plants against Mycobacterium tuberculosis and Mycobacterium bovis strains*. BMC complementary and alternative medicine, 2013. **13**(1): p. 1-6.
15. Swami, H.S., et al., *Extraction technologies for medicinal and aromatic plants*. Trieste: United Nations Industrial Development Organization and the International Centre for Science and High Technology, 2008. **200**: p. 266.
16. Fauziyah, P.N., E.Y. Sukandar, and D.K. Ayuningtyas, *Combination effect of antituberculosis drugs and ethanolic extract of selected medicinal plants against multi-drug resistant Mycobacterium tuberculosis isolates*. Scientia pharmaceutica, 2017. **85**(1): p. 14.
17. Organization, W.H., *Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis*. 2018.
18. Chinsembu, K.C., *Tuberculosis and nature's pharmacy of putative anti-tuberculosis agents*. Acta Tropica, 2016. **153**: p. 46-56.
19. Koul, A., et al., *The challenge of new drug discovery for tuberculosis*. Nature, 2011. **469**(7331): p. 483-490.
20. Bunalema, L., et al., *Potential of Zanthoxylum leprieurii as a source of active compounds against drug resistant Mycobacterium tuberculosis*. BMC Complementary and Alternative Medicine, 2017. **17**(1): p. 1-6.

21. Haas, M.K. and R.W. Belknap. *Updates in the treatment of active and latent tuberculosis*. in *Seminars in respiratory and critical care medicine*. 2018. Thieme Medical Publishers.
22. Makgatho, M., et al., *Evaluation of the anti-mycobacterial, anti-oxidative and anti-proliferative activities of Rubia cordifolia ethanolic leaf extract sub-fractions in human lymphocytes and neutrophils*. African Journal of Traditional, Complementary and Alternative Medicines, 2017. **14**(5): p. 181-187.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PercentageinhibitionforcombinationofstandardantiTBsandmedicinalplants.xlsx](#)